All In Biotech

Free tool

FAERS Monitor: Jevtana Kit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201023 or its brand name (Jevtana Kit, Cabazitaxel). Reports on generic versions are filed under their own applications.

Reports

3,517

Serious

0

0% of reports

Hospitalization

1,348

Death reported

705

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • febrile neutropenia250
  • malignant neoplasm progression238
  • fatigue210
  • prostatic specific antigen increased202
  • diarrhoea191
  • disease progression187
  • anaemia180
  • neutropenia174
  • pyrexia172
  • drug ineffective162
  • death155
  • asthenia139
  • dyspnoea138
  • metastases to bone130
  • haematuria125

Reports by year received

View as table
YearReports

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,642 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal25022.620.15,141
haematuriaSignal12521.918.42,468
malignant neoplasm progressionSignal23813.912.32,850
disease progressionSignal1879.58.21,413
neutropeniaSignal1747.76.61,006
anaemiaSignal1805.64.9690
pyrexiaSignal1723.02.6227
astheniaSignal1392.21.993
diarrhoea1911.81.565
fatigue2101.61.450
dyspnoea1381.51.220
death1551.10.91
drug ineffective1620.70.616
prostatic specific antigen increased2020.00.01,203,083
metastases to bone1300.00.0772,132

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.